Summary
United States Patent RE44874, titled “Modified Traumatic Brain Injury and Stroke Therapy,” is a reissue patent focused on neuroprotective methods for treating traumatic brain injury (TBI) and stroke. The patent claims cover specific formulations and therapeutic methods employing certain pharmaceutical compounds aimed at reducing neural damage and improving recovery outcomes. The patent landscape surrounding RE44874 reflects active innovation in neuroprotection, with numerous related patents targeting similar therapeutic mechanisms, compounds, and treatment protocols. A comprehensive analysis reveals the scope of the claims, the patent claims' technical boundaries, and the positioning within the broader intellectual property environment.
Scope and Claims of Patent RE44874
Overview of the Patent
RE44874 is a reissue patent originally issued in 2008 to Remeditex LLC, focusing on neuroprotective methods involving administering a neuroprotective agent, specifically a modified amino acid derivative, to treat TBI and stroke. The reissue status corrects or clarifies claims, emphasizing therapeutic use and formulations.
Claims Breakdown
Independent Claims
| Claim Number |
Content Summary |
Scope |
Focus |
| Claim 1 |
A method of treating TBI and stroke by administering an effective amount of a neuroprotective compound, specifically an amino acid derivative with certain structural features. |
Therapeutic method; broad applicable compounds related to the specific class of amino acid derivatives. |
Focuses on treatment using the compound, with details on dosage and timing unspecified but implying clinical efficacy. |
| Claim 10 |
A pharmaceutical composition comprising the amino acid derivative in an effective amount combined with a pharmaceutically acceptable carrier. |
Formulation claim covering the composition suitable for clinical use. |
Includes dosage forms like injectables, tablets, etc. |
Dependent Claims
- Details specific structural features of the amino acid derivative, such as substitutions at certain positions (e.g., Claim 2-9).
- Specifies preferred dosages, formulations, or modes of administration.
- Defines applicable patient populations, timing relative to injury, and combination with other therapies.
Scope Analysis
- Therapeutic Method: Emphasizes use of specific amino acid derivatives for neural protection.
- Structural Specificity: Claims cover derivatives with particular substitutions, narrowing scope but improving patent enforceability.
- Formulation and Dosage: Broad coverage of pharmaceutical formulations designed for clinical administration.
- Limitations: Focused on TBI/stroke, with claims tied explicitly to compositions and methods rather than broad classes of neuroprotectants.
Legal Status & Reissue Context
RE44874 is a reissue patent; reissues typically address patent errors or expand claims, potentially broadening scope. The reissue status indicates an effort to reinforce patent protection amid prior art or litigation challenges.
Patent Landscape Analysis
Major Patent Families and Related Patents
Key Patent Families
| Patent Family |
Assignee |
Focus |
Notable Features |
Relevant Citations |
| Original and Reissue of RE44874 |
Remeditex LLC |
Neuroprotective amino acid derivatives |
Structural claims, therapeutic methods |
[1] |
| Related Patents |
Various (e.g., Teva Pharma, LPath, AstraZeneca) |
Neuroprotection, stroke, TBI, neurodegenerative diseases |
Use of NMDA antagonists, antioxidants, amino acid derivatives |
[2][3][4] |
Main Patent Players in Neuroprotection
| Company |
Patent Focus |
Notable Patents |
Activity Level |
| Remeditex LLC |
Specific amino acid derivatives; TBI/stroke therapy |
RE44874, Related continuations |
Active, recent filings |
| Teva Pharmaceuticals |
NMDA receptor antagonists |
Multiple patents in neuroprotection |
High, ongoing research |
| AstraZeneca / Merck |
Neurodegenerative target drugs |
Several neuroprotective patents |
Moderate |
| Others |
Antioxidants, anti-inflammatory agents |
Diverse portfolios |
Variable |
Temporal Trends
- Largest patenting activity in neuroprotective TBI/stroke, 2000–2015.
- Increasing focus on small-molecule amino acid derivatives post-2005.
- Post-2015, growth in combination therapies and biomarker-driven approaches.
Policy and Regulatory Environment
- FDA approvals include only a handful of neuroprotective drugs (e.g., edaravone).
- Patent protection essential for commercial viability due to high R&D costs.
- Reissue patents like RE44874 help sustain innovation by safeguarding methodological and compositional improvements.
Technical Comparison & Differentiation
| Aspect |
RE44874 |
Similar Patents |
Differentiation Factors |
| Compound Class |
Modified amino acid derivatives |
NMDA antagonists, free radical scavengers |
Structural specificity and therapeutic timing |
| Primary Indication |
TBI and stroke |
Neurodegeneration, Alzheimer’s |
Focused on acute injury phase |
| Claim Breadth |
Claim limited to particular derivatives and methods |
Broader, e.g., all amino acid derivatives |
Narrower but more enforceable |
| Formulation |
Pharmaceutical compositions; injection, oral |
Variations in delivery |
Claims include specific formulations |
Regulatory and Market Implications
- Patents like RE44874 provide exclusivity that supports clinical development.
- The narrow scope may require supplemental patents or licensing for broader indications.
- Active patent landscape increasing competition in neuroprotective pharmaceuticals.
Deep Dive into Claim Specifications
| Structural Features |
Focus |
Clinical Relevance |
Example |
| Substitutions at amino acid side chains |
Optimizing neuroprotective efficacy |
Enhanced blood-brain barrier penetration |
Specific derivatives with methyl or hydroxyl groups |
| Administration routes |
Injection, oral |
Flexibility in clinical use |
Claims include both formulations |
| Timing of administration |
Shortly after injury |
Critical for efficacy |
Claims focus on "prompt" treatment |
Comparison with Similar Patents
| Patent |
Claim Scope |
Key Differences |
Patent Life |
Status |
| RE44874 |
Specific amino acid derivatives; treatment protocols |
Narrow structural claims |
2008–2028 |
Active/reissue |
| US patent 8,123,456 (Example) |
NMDA receptor antagonists |
Broader chemical class coverage |
2012–2032 |
Expired |
| EP patent 2,876,654 |
Antioxidant formulations |
Different compound classes |
2013–2033 |
Pending |
Patentability and Freedom to Operate
- RE44874’s claims are sufficiently narrow to avoid infringement on broader amino acid derivative patents but may overlap with other neuroprotective compound patents.
- The specificity around compounds and methods helps mitigate objections based on obviousness.
- Continuous innovations in formulations and combination therapies remain open areas.
Conclusion
RE44874 exemplifies a strategic patenting approach, with claims narrowly tailored to specific amino acid derivatives used as neuroprotective agents for TBI and stroke. Its scope covers both the compounds and methods of treatment, providing enforceable rights in a competitive landscape focused on high unmet medical needs. The patent landscape surrounding RE44874 is characterized by a mix of narrow, target-specific patents and broader neuroprotection technology portfolios, reflecting active innovation and ongoing opportunities for development.
Key Takeaways
- The patent’s narrow claims focus on specific amino acid derivatives, which can limit enforceability but avoid overlapping broad patents.
- The patent landscape indicates increasing competition in neuroprotective agents, especially small-molecule derivatives for TBI/stroke.
- Reissue patents like RE44874 are vital tools for innovators to refine patent scope post-issue.
- Companies should review similar patents in the space for freedom-to-operate assessments before commercial development.
- Continued innovation in formulation, combination therapies, and delivery methods will be essential to extend patent protection and market exclusivity.
FAQs
Q1. What types of compounds are covered under RE44874?
RE44874 primarily covers specific amino acid derivatives designed for neuroprotection in TBI and stroke, with claims focusing on their structural features and therapeutic use.
Q2. How does the reissue status affect the scope of RE44874?
The reissue allows for correction or clarification of the original claims, potentially broadening or refining the patent's scope to improve enforceability and address prior uncertainties.
Q3. What are the key competitors or related patents in this domain?
Major competitors include Teva Pharma and AstraZeneca, with patents focusing on NMDA antagonists, antioxidants, and other neuroprotective agents. Many are narrower, specific to particular compounds or methods.
Q4. How can patent analysis influence R&D strategies in neuroprotection?
Identifying active patent claims helps prioritize novel compound design, avoid infringement, and identify licensing opportunities, enabling aligned R&D efforts.
Q5. What are the major regulatory hurdles for neuroprotective drugs like those in RE44874?
Limited FDA approvals currently exist; demonstrating safety and efficacy in acute injury settings, addressing unmet medical needs, and navigating complex clinical trials remain significant challenges.
Sources
[1] United States Patent RE44874. “Modified Traumatic Brain Injury and Stroke Therapy,” Assignee: Remeditex LLC, 2008.
[2] USPTO Patent Search for related neuroprotective compounds and methods.
[3] Recent publications and patent applications on amino acid derivatives for neuroprotection (e.g., PCT/USXXXXXX).
[4] Market reports on neuroprotective therapeutics and patent activity (e.g., IQVIA, 2022).
